Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post-Authorization Safety Survey Among Physicians.

ABSTRACT:

Background

Interstitial lung disease (ILD)/pneumonitis is an important safety risk of trastuzumab deruxtecan (T-DXd) treatment. This study assessed the effectiveness of additional risk minimization measures (aRMMs) outlined in the educational material (EM) for the product regarding physicians' awareness, knowledge, and implementation related to the risk, early detection, and management of ILD/pneumonitis.

Methods

A web-based survey was conducted among prescribers of T-DXd from seven European countries (Austria, Denmark, France, Germany, Sweden, Spain, and the UK) between 03/2021 and 11/2022. The overall effectiveness of the aRMMs was determined as the percentage of physicians correctly responding to questions in the awareness, knowledge, and implementation domains, with cut-

SUBMITTER: Wientzek-Fleischmann A 

PROVIDER: S-EPMC12426362 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature